Serum calcification propensity is associated with HbA1c in type 2 diabetes mellitus. Issue 1 (24th February 2021)

• Record Type: Journal Article
• Authors: Mencke, Rik; van der Vaart, Amarens; Pasch, Andreas; Harms, Geert; Waanders, Femke; Bilo, Henk J G; van Goor, Harry; Hillebrands, Jan-Luuk; van Dijk, Peter R
• Is Part Of: BMJ open diabetes research and care. Volume 9:Issue 1(2021)
• Publication Date: 2021-02-24
• Subjects: diabetes mellitus -- type 2 -- calcium -- cardiovascular system -- hyperglycaemia; Diabetes -- Periodicals; 616.462005
• DOI: 10.1136/bmjdrc-2020-002016
• Languages: English
• ISSNs: 2052-4897

Abstract

Abstract : Introduction: Serum calcification propensity is emerging as an independent predictor for cardiovascular outcomes in high-risk populations. Calcification propensity can be monitored by the maturation time of calciprotein particles in serum (T50 test). A low T50 value is an independent determinant of cardiovascular morbidity and mortality in various populations. Aim was to investigate the T50 and its relationship to type 2 diabetes mellitus. Research design and methods: Using nephelometry, serum T50 was cross-sectionally measured in 932 stable patients with type 2 diabetes mellitus (55% male) with a median age of 66 (62–75) years, diabetes duration of 6.5 (3.0–10.2) years and hemoglobin A1c (HbA1c) of 49 (44–54) mmol/mol. Results: Serum T50 was normally distributed with a mean value of 261±66 min. In linear regression, serum T50 was lower in women and current smokers. A lower T50 value was found in patients with a higher HbA1c or higher systolic blood pressure, insulin users and patients with a longer history of diabetes. The association with HbA1c was independent of other determinants in multivariable analysis. There was no association between T50 and previous macrovascular events or the presence of microvascular disease. Conclusions: Serum calcification propensity is independently associated with glycemic control, suggesting that a lower HbA1c may be associated with better cardiovascular outcomes. Retrospective analysis could not establish an association between a history of macrovascular events and T50, and prospective studies will have to be performed to address this hypothesis. Trial registration number: NCT01570140 .